GCP and Quality in "Regulation (EU) 536/2014 on clinical trials on medicinal products for human use and repealing Directive 2001/20/EU

被引:0
|
作者
Filibeck, Umberto [1 ]
Sanzi, Eleonora [1 ]
机构
[1] Univ Roma Tor Vergata, Rome, Italy
关键词
EU Regulation No 536/2014; Directive; 2001/20/EC; Good Clinical Practice; Quality; Clinical Trials legislation;
D O I
10.1016/j.microc.2017.08.003
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Among the several new provisions foreseen by the EU Regulation (R) 2014/536 on Clinical Trials (CTs) repealing Directive (D) 2001/20/EC, this article focuses on the identification of possible critical points leading to potential incongruences regarding Good Clinical Practice (GCP). EU D foresees the obligation to be in compliance with GCP detailed guidelines, while the R foresees the obligation to be in compliance only with the GCP principles. Many of the GCP detailed aspects have been transposed in the R and the R provides to be in compliance with GCP quality standards. Nevertheless, other GCP aspects, which have direct or indirect ethical implication in CTs, will not be mandatory in the EU. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:40 / 42
页数:3
相关论文
共 50 条
  • [1] Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use: an overview
    Petrini, Carlo
    ANNALI DELL ISTITUTO SUPERIORE DI SANITA, 2014, 50 (04): : 317 - 321
  • [2] Informed consent to the clinical trial in the critical patient. Introduction to the EU Regulation n. 536/2014 on the clinical trial of medicinal products for human use that repeals Directive 2001/20 / EC
    Savonitto, Stefano
    Coppola, Teresa
    Braglia, Paola
    Ciccone, Alfonso
    GIORNALE ITALIANO DI CARDIOLOGIA, 2016, 17 (05) : 326 - 334
  • [3] The national legislation accompanying the approval procedure for clinical trials of medicinal products for human use under Regulation (EU) No. 536/2014
    Frech, Marion
    Dexel, Florian
    Burgard, Margareta
    Seibel, Yvonne
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2023, 66 (01) : 12 - 20
  • [4] REGULATION (EU) NO 536/2014 ON CLINICAL TRIALS AND VULNERABLE GROUPS
    Marino Hernandez, Eduardo L.
    CUADERNOS DE BIOETICA, 2015, 26 (88): : 427 - 430
  • [5] Safety reporting in clinical trials: new regulatory requirements arising by the regulation (EU) No 536/2014 of the European parliament and of the council of 16 April 2014 on clinical trials on medicinal products for human use
    Duranton, S.
    Autexier, M. D.
    Carlhant-Kowalski, D.
    Chiffoleau, A.
    Jamet, A.
    Jobert, A.
    Morvan, F.
    Mouchel, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 71 - 71
  • [6] Principles of the EU Clinical Trials Regulation No 536/2014 What will change?
    Mende, Aylin
    Frech, Marion
    Riedel, Claudia
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2017, 60 (08) : 795 - 803
  • [7] The new regulation on the pharmacovigilance of medicinal products for human use. (Directive 2010/84/EU and regulation [EU] no. 1235/2010)
    Conce, Marie-Catherine Chemtob
    MEDECINE & DROIT, 2012, (115): : 114 - 120
  • [8] Main characteristics of the new authorisation procedure for clinical trials with medicinal products according to regulation (EU) no 536/2014 and the cooperation between the member states
    Sudhop, Thomas
    Riedel, Claudia
    Krafft, Hartmut
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2023, 66 (01) : 3 - 11
  • [9] Evaluation of clinical trials on medicinal products by ethics committees: changes due to the new EU Regulation 536/2014 (CTR) and necessary harmonization measures
    Raffauf-Seufert, Claudia
    Grass, Guido
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2023, 66 (01) : 45 - 51
  • [10] An EU Comparative Analysis of the Regulation of Clinical Trials Supervisory Bodies in the Aftermath of Regulation 536/2014
    de Miguel Beriain, Inigo
    Chortara, Theodora
    Duardo-Sanchez, Aliuska
    Feeney, Oliver
    Felzmann, Heike
    Fernandez de Uzquiano, Emma
    Lievevrouw, Elisa
    Marelli, Luca
    Mattsson, Titti
    Herrmann, Janne Rothmar
    Minssen, Timo
    Pulice, Elisabetta
    Raposo, Vera Lucia
    Robienski, Jurgen
    Penasa, Simone
    Van Hoyweghen, Inc
    EUROPEAN PUBLIC LAW, 2020, 26 (02): : 307 - 329